Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.
about
Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyPalmatine inhibits growth and invasion in prostate cancer cell: Potential role for rpS6/NFκB/FLIP.Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate CancerPhase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patientsComparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer.Current and emerging therapies for bone metastatic castration-resistant prostate cancer.Galectins as new prognostic markers and potential therapeutic targets for advanced prostate cancers.Targeting kallikrein-related peptidases in prostate cancer.Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancerCurrent concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials.Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.Therapy monitoring of skeletal metastases with whole-body diffusion MRI.
P2860
Q26825053-D782ED0D-8755-4C0A-8B5E-9EFA60B16A45Q34429968-1E6DEDE5-6919-45C9-9E5E-CDD3A522FD88Q34477201-241D2325-9305-4787-A0CA-866AA9207E86Q35328550-B0C154CF-D371-4737-A9A7-D66D564B70D9Q35655761-EB02DB1C-4ABB-4239-A371-13E2D042DA09Q35932706-076FEAD2-ECB4-441D-9A8E-A4245F860BF3Q36358303-DF572AFF-ADC7-476E-8D24-0DB40C2E6DF9Q38160862-7080082B-DC06-493A-978B-D2C3FC4999DCQ38191293-B64E55A7-2945-4EF0-90F0-7415F8776A8EQ38205964-5AE281C7-E817-4D73-8135-D5E96D7064EAQ38599748-349B8491-0FB5-4817-AE99-EFEB8CF223C6Q41369617-0050C9C4-B437-4FE1-913B-73B701D94B18Q44663325-4057C964-B540-404C-982A-670CFC58E12BQ51114179-45D87AF2-362A-449B-9F08-F4B171C04E7F
P2860
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Challenges to improved therape ...... recent successes and failures.
@ast
Challenges to improved therape ...... recent successes and failures.
@en
type
label
Challenges to improved therape ...... recent successes and failures.
@ast
Challenges to improved therape ...... recent successes and failures.
@en
prefLabel
Challenges to improved therape ...... recent successes and failures.
@ast
Challenges to improved therape ...... recent successes and failures.
@en
P2093
P2860
P356
P1476
Challenges to improved therape ...... recent successes and failures.
@en
P2093
Cindy H Chau
William D Figg
Xuan Huang
P2860
P2888
P356
10.1186/1756-8722-5-35
P5008
P577
2012-07-02T00:00:00Z
P5875
P6179
1020261282